Adefovir

generic for Hepsera

Adefovir Warnings

Severe worsening of hepatitis (rarely including death) has occurred when treatment with adefovir dipivoxil is stopped. When you are instructed to stop taking this medication, your doctor will monitor you closely for signs of worsening hepatitis. If you are instructed to stop taking this medication, be sure to keep all doctor and lab appointments after you stop taking this drug.

Rarely, severe (sometimes fatal) liver and blood acid-base balance problems (lactic acidosis) have occurred in patients (especially if overweight) while using similar types of medication (nucleoside analogs such as didanosine or stavudine). Tell your doctor right away if you have unusual weakness or fatigue, dark urine, yellowing of the skin or eyes, abdominal or stomach pain, drowsiness, muscle aches or weakness, trouble breathing (such as rapid breathing or very shallow breathing), or fast or irregular heartbeat.

In patients with kidney disease, adefovir dipivoxil can cause kidney problems. Tell your doctor right away if you develop signs of kidney problems such as a change in the amount of urine.

If you get or have HIV infection that is not being treated with medication, adefovir dipivoxil may cause your HIV infection to become untreatable with the usual HIV drugs (development of HIV resistance). Talk to your doctor or pharmacist for more details.
  • Store at room temperature. Protect from moisture.
  • Warning: To prevent loss of effect, keep drug in original container. Close tightly right away after each use.
  • Read the boxed warning information for this medication.

Lactation Warnings

  • LOW MW, POTENTIAL FOR SERIOUS ADVERSE EFFECTS (NEPHROTOXICITY AND HEPATITIS)

Pregnancy Warnings

  • Limited data with use in pregnant women are insufficient to determine whether there is risk of major birth defects or miscarriage. Animal data suggest no developmental toxicity at doses greater than 10 times the maximum recommended human dose. Consider maternal treatment benefits versus potential fetal/neonatal adverse outcomes.